Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 3Hematologic Neoplasms 3Multiple Myeloma 2Melanoma 2Lymphoma, Non-Hodgkin 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Pancreatic Carcinoma 1Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Respiratory Tract Infections 1Respiratory Distress Syndrome 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Lymphoma, Mantle-Cell 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immune-related Adverse Events 1

Interventions

tocilizumab 1XAV-19 1Ribavirin 1Immunoglobulin G 1Gelsolin 1Disulfides 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pneumonia × tocilizumab × Clear all
NCT04370834 2025-02-04

Tocilizumab for Patients With Cancer and COVID-19 Disease

National Cancer Institute (NCI)

Phase 2 Terminated
1 enrolled 10 charts
Other hematologic neoplasm

Pneumonia, Respiratory Distress Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡